Cancer Research and Treatment

Eun Mi Nam

4 Articles

Cancer of Unknown Primary Finally Revealed to Be a Metastatic Prostate Cancer: A Case Report: Jung Yeon Cho, Eun Jin Shim, In Seon Kim, Eun Mi Nam, Moon Young Choi, Kyung Eun Lee, Yeung Chul Mun, Chu Myoung Seoung, Soon Nam Lee, Dong Eun Song, Woon Sup Han; Cancer Res Treat. 2009;41(1):45-49. Published online March 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.1.45

The vast majority of patients with metastatic prostate cancer present with bone metastases and high prostate specific antigen (PSA) level. Rarely, prostate cancer can develop in patients with normal PSA level. Here, we report a patient who presented with a periureteral tumor of unknown primary site that was confirmed as prostate adenocarcinoma after three years with using specific immunohistochemical examination. A 64-year old man was admitted to our hospital with left flank pain associated with masses on the left pelvic cavity with left hydronephrosis. All tumor markers including CEA, CA19-9, and PSA were within the normal range. After an exploratory mass excision and left nephrectomy, the pelvic mass was diagnosed as poorly differentiated carcinoma without specific positive immunohistochemical markers. At that time, we treated him as having a cancer of unknown primary site. After approximately three years later, he revisited the hospital with a complaint of right shoulder pain. A right scapular mass was newly detected with a high serum PSA level (101.7 ng/ml). Tissues from the scapular mass and prostate revealed prostate cancer with positive immunoreactivity for P504S, a new prostate cancer-specific gene. The histological findings were the same as the previous pelvic mass; however, positive staining for PSA was observed only in the prostate mass. This case demonstrates a patient with prostate cancer and negative serological test and tissue staining that turned out to be positive during progression. We suggest the usefulness of newly developed immunohistochemical markers such as P504S to determine the specific primary site of metastatic poorly differentiated adenocarcinoma in men.

Citations

Citations to this article as recorded by

A Unique Case of Prostate Carcinoma Presenting as Retroperitoneal Lymphadenopathy With Normal Levels of Prostate-Specific Antigen and a Prostate of Normal Size: A Case Report
Swapnil Patil, Mayank Mundada, Pradnya M Diggikar, Raju Hansini Reddy, Sree Vidya Yekkaluru
Cureus.2024;[Epub] CrossRef
Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review
Xinbing Sui, Yan Hu, Cheng Zhang, Hongming Pan, Da Li
Oncology Letters.2016; 12(2): 1074. CrossRef
Metastasis of prostate carcinoma in the mandible manifesting as numb chin syndrome
Secil Aksoy, Kaan Orhan, Sebnem Kursun, Mehmet Eray Kolsuz, Berkan Celikten
World Journal of Surgical Oncology.2014;[Epub] CrossRef

9,561 View
56 Download
3 Crossref

Clinical Features and Prognosis of Lung Cancer with Brain Metastasis: Kyung Eun Lee, Eun Mi Nam, He Jin Lee, Seung Hyun Nam, Do Yeun Kim, Seock Ah Im, Chu Myung Seong, Soon Nam Lee, Kyung Ja Lee; Cancer Res Treat. 2001;33(3):250-255. Published online June 30, 2001; DOI: https://doi.org/10.4143/crt.2001.33.3.250

Abstract PDF

PURPOSE
Brain metastasis is estimated to occur in 20~40% of solid tumor patients and the most common primary tumor is lung cancer. Even though the prognosis of brain metastasis is grave and the 1-year survival rate is only 15%, symptom palliations are made with whole brain radiation therapy. We retrospectively evaluated the clinical features and prognostic factors of lung cancer with brain metastasis.
MATERIALS AND METHODS
From January 1987 to October 1999, 50 lung cancer patients with brain metastasis underwent whole brain radiation therapy. We reviewed the improvement in neurologic symptoms and survival according to the following parameters; performance status, histological type, presence of brain metastasis at the initial diagnosis of lung cancer, presence of extracranial metastasis, multiplicity of brain lesion, presence of primary lung symptom and treatment modalities.
RESULTS
The most frequent symptom with brain metastasis was a headache (50%). Palliation of the headache and other symptoms was achieved in 81% of the patients. Median overall survival after brain metastasis was 21 weeks and the 1 year survival rate was 15%. Patients without extracranial metastasis had a longer median survival than those with, 38 weeks versus 15 weeks, respectively (p=0.01).
CONCLUSION
In lung cancer with brain metastasis, neurologic symptoms can be palliated with whole brain radiation therapy, and in this study among such patients, absence of extracranial metastasis can be a good prognostic factor.

Citations

Citations to this article as recorded by

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
Cancers.2023; 15(11): 3015. CrossRef

4,608 View
48 Download
1 Crossref

Determination of Serum CEA Level in Primary Lung Cancer: Jin Hyuk Choi, Jung Hyun Chang, Soon Nam Lee, Eun Mi Nam, Ki Ryung Park, Sa Young Park, Hyo Jin Lee, Sung Min Cho, Young Sun Kim, Ka Eun Woo, Na Young Lee, Na Young Lee, Kwang Ho Kim; J Korean Cancer Assoc. 1996;28(2):281-286.

Abstract PDF: Background
The role of serum carcinoembryonic antigen(CEA) as a tumor marker in primary lung cancer remains unanswered. Several reports suggested that usefulness of serum CEA was limited to specific histologic types or clinical situations. Methods: Serum levels of CEA were determined in 126 patients with primary lung cancer and its correlation with clinico-pathologic characteristics was investigated. Results: Serum CEA was positive (defined as>5ng/ml) in 71 patients(56.3%). The positivity of serum CEA was significantly higher in adenocarcinoma(72.3%) than that in squamous cell carcinoma(46.5%) and small cell carcinoma(44.0%) (p=0.025). There was no significant difference in positivity of CEA according to sex and stages. Conelueion: Serum CEA does not seem to be standard tumor marker of primary lung cancer. However, it could be useful as prognostic factor or monitor of treatment results, especially in adenocarcinoma.

3,450 View
16 Download

Psychometric Validation of Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients: Hong Jun Kim, Eun Hee Jung, Jung Hye Kwon, Yu Jung Kim, Su-Jin Koh, Myung Ah Lee, Jung Hun Kang, Sun Young Rha, Eun Mi Nam, Sun Kyung Baek, Ha Yeon Lee, Hun Ho Song, Young-Woong Won, Hanbyul Lee; Received July 26, 2024 Accepted December 4, 2024 Published online December 5, 2024; DOI: https://doi.org/10.4143/crt.2024.706 [Accepted]

Abstract PDF: Purpose
Identifying the palliative care needs of patients with advanced cancer is important for maintaining quality of life and timely transition to palliative care. We aimed to validate the Korean Sheffield Profile for Assessment and Referral for Care (K-SPARC) in such patients and establish its psychometric properties, including reliability, validity, and responsiveness to change.
Materials and Methods
We used the forward-back translated version of SPARC, which was verified through a pilot study, to assess the palliative care needs of patients with advanced cancer. Reliability was evaluated by internal consistency using Cronbach's alpha coefficients and test-retest reliability. Criterion validity was analyzed against other questionnaires, including the Korean versions of the Functional Assessment of Cancer Therapy-General (FACT-G Korean) and Korean versions of the Edmonton Symptom Assessment System (K-ESAS). Factor analysis was used to assess construct validity.
Results
Two hundred fifty-nine patients were included from 2019 to 2022. Forty-nine percent of all patients were women, and the median age was 63 years. Cronbach’s alpha coefficient (range, 0.642–0.903) and test-retest reliability (range, 0.574–0.749) indicated acceptable reliability. The correlation coefficients between K-SPARC and FACT-G Korean suggested significant criterion validity. The correlation coefficients for the physical, social, emotional, and functional domains were 0.701, 0.249, 0.718, and 0.511, respectively (p-value <0.001, all). Factor analysis demonstrated satisfactory construct validity of the tool.
Conclusion
This study demonstrated the utility of K-SPARC as an evaluation tool for providing palliative care to patients with advanced cancer through psychometric validation; the tool had good internal consistency, reliability, and acceptable validity.

137 View
11 Download

Author index